메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

BON Announces Reciept of Nasdaq Compliance Letter

XI'AN, China, Aug. 5, 2025 -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or "the Company"), a leading provider of bio-ingredient solutions for the natural health and personal care industries, today announced reciept of compliance notification from the Nasdaq Stock Market LLC. As previously reported on a Form 6-K filed with the U.S. Securities and Exchange Commission on July 11, 2025, Bon Natural Life Limited ( "the Company") received notification from the Nasdaq Hearings Panel (the "Panel") that the Company had regained compliance with Listing
- 김갑성 기자
- 2025-08-05 21:00
A Midsummer Night's Dream: Yaber, BLUETTI, and RayNeo Illuminate the Summer Outdoors

NEW YORK, Aug. 5, 2025 -- Yaber, a pioneer in entertainment projectors, today teams up with portable power innovator BLUETTI and AR glasses leader RayNeo to launch "A Midsummer Night's Dream," a cross-brand campaign celebrating the quiet magic of summer nights and the expanding possibilities of outdoor living. The collaboration brings together three technologies—projection, power, and next-generation visuals—to elevate shared experiences under the open sky. At the heart of the experience are Yaber's portable projectors: the T2 Plus GTV and the T1 Pro. Purpose-
- 김장윤(JASON KIM) 기자
- 2025-08-05 21:00
Next Level Aviation® Completes Recap of Turning Rock Partners

NLA completed the full redemption of Turning Rock's preferred equity investment ahead of schedule DANIA BEACH, Fla., Aug. 5, 2025 -- Next Level Aviation® (NLA), a leader in the global distribution of used serviceable materials (USM) for all Boeing and Airbus commercial aircraft and associated jet engine platforms, has fully redeemed Turning Rock Partners' (TRP) 2019 preferred equity investment. NLA completed the full redemption of TRP's stake, ahead of schedule, in mid- June 2025. Next Level Aviation® Chairman & CEO Jack Gordon stated, "We are extremely
- 황정호 기자
- 2025-08-05 21:00
넥스트레벨에비에이션®, 터닝록파트너스와의 자본 재조정 완료

NLA, 예정보다 조기에 터닝록의 우선주 투자 전액 상환 완료 다이아 비치, 플로리다주, 2025년 8월 5일 -- 보잉(Boeing)과 에어버스(Airbus) 상업용 항공기 및 관련 제트 엔진 플랫폼을 위한 중고 서비스 가능한 자재(USM)의 글로벌 유통을 선도하는 기업인 넥스트레벨에비에이션(Next Level Aviation®, 이하 'NLA')이 2019년 터닝록파트너스(Turning Rock Partners, 이하 'TRP')가 한 우선주 투자를 전액 상환했다. NLA는 예정보다 앞선 2025년 6월 중순에 TRP의 지분 상환을 완료했다. 제이크 고든(Jack Gordo) 넥스트레벨에비에이션® 회장 겸 최고경영자(CEO)는 "터닝록파트너스가 한 투자 상환을 완전히 마무리하게 되어 매우 기쁘다"면서 "투자 기간 동안 재정적 및 운영적 차원에서 우리를 지원해 준 TRP 팀에게 다시 한번 감사의 말씀을 드리며, 앞으로도 TRP 팀 전체가 개인적으로나 포트폴리오 투자로나 모두 항상 성공하기를 바란다"고 말했다. 고든 회장은 이어 "이번 경영진 주도
- 황정호 기자
- 2025-08-05 21:00
TECHTRONIC INDUSTRIES DELIVERS STRONG FIRST HALF PERFORMANCE

GROWING SALES TO US$7.8 BILLION, NET PROFIT INCREASED TO US$628 MILLION HONG KONG, Aug. 5, 2025 -- Global cordless power tool, outdoor power equipment and floorcare & cleaning company Techtronic Industries Co. Ltd. ("TTI" or the "Group") (stock code: HK: 0669, ADR symbol: TTNDY) is pleased to announce the unaudited consolidated results of the Company and its subsidiaries for the six-month period ended June 30, 2025. TTI grew sales in the first half of 2025 to US$7.8 billion, up 7.1% in reported currency and 7.5% in local currency. Its two leading brands, MILWAUK
- 황정호 기자
- 2025-08-05 20:42
Recon Awarded Mega $5.85 Million Contract to Provide Upgrades Service for Large Mid-Asia Gas Field

BEIJING, Aug. 5, 2025 -- Recon Technology Ltd. ("Recon" or "the Company"), a China-based provider of oilfield and low-carbon energy services, announced today that one of its domestic affiliated entities has been awarded major contracts to upgrade and retrofit related automation systems for some large Asian gas field. These contracts are valued at approximately $5.85 million, and the services provided by the entity in these contracts are expected to be completed within the next calendar year. These maintenance services are intended to ensure the capacity supply of the gas f
- 황정호 기자
- 2025-08-05 20:30
First-of-Its-Kind Japan Preschool Exchange Lets Global Families Experience Real Japanese School Life -- With a Little Help from Peppa Pig

TOKYO, Aug. 5, 2025 -- Japan Preschool Exchange (JPE), a cultural exchange program, invites global families to experience daily life at real Japanese preschools—from snowy play to rice harvesting in nature-rich communities. Families can join for 1 to 3 weeks with no Japanese knowledge required. JPE partners with over 30 trusted preschools nationwide, supporting local sustainability and offering unforgettable experiences. Since launching in 2021, JPE has welcomed over 1,000 participants, with 95% saying they would return. The program has earned multiple government awards. Founde
- 김장윤(JASON KIM) 기자
- 2025-08-05 20:00
iNtRON Bio, Demonstrated Toxin-Neutralizing Effect of IMPA™ Phage Engineering Technology in Colorectal Cancer Model and Completed the US Patent Application

[ 메디채널 김갑성 기자 ] • Successful validation of payloaded anti-colibactin toxin phage using IMPA™ technology • Demonstrated 'Dual-target Therapeutic Strategy' by bacterial eradication and toxin neutralization • Filed the US patent application for the candidate substance and preclinical studies including PoC underway BOSTON and SEOUL, South Korea, Aug. 5, 2025 -- Recently, a specific genotype of E. coli that may cause colorectal cancer has been detected in commonly eaten leafy vegetables such as lettuce, raising consumer concerns. Among these strains, pks+ E. coli is of particular conce
- 김갑성 기자
- 2025-08-05 20:00
Court Sides with Cardiovalve in Edwards patent spat

HANGZHOU, China, Aug. 5, 2025 -- Venus Medtech (Hangzhou) Inc. ("Venus Medtech", Stock Code: 02500.HK) recently announced a decisive legal victory for its wholly-owned subsidiary Cardiovalve Ltd. ("Cardiovalve") against Edwards Lifesciences Corporation and Edwards Lifesciences LLC. (collectively "Edwards"). The United States Court of Appeals for the Federal Circuit ("CAFC") has formally issued its mandate in Case 23-1515, affirming the Patent Trial and Appeal Board's ("PTAB") December 2022 ruling that upheld the validity of Cardiovalve's paten
- 김갑성 기자
- 2025-08-05 20:00
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Small Molecule Oral GLP-1R Agonist, ASC30, in Participants with Obesity or Overweight

- 13-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of two oral formulations of ASC30, a once-daily tablet, in 125 participants with obesity or overweight. - All 125 participants enrolled in just over one month; topline data expected in the fourth quarter of 2025. HONG KONG, Aug. 5, 2025 -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today completion of enrollment in its U.S. 13-week Phase IIa study evaluating ASC30, a small molecule oral GLP-1 receptor (GLP-1R) agonist for the treatment of obesity (NCT0700290
- 김갑성 기자
- 2025-08-05 18:50

이전

41 42 43 44 45 46 47 48 49 50

많이 본 기사

최근기사

2025-08-21_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 21일 14시 20분